Skip to main content
. Author manuscript; available in PMC: 2014 Oct 3.
Published in final edited form as: Cancer. 2010 Nov 29;117(10):2145–2155. doi: 10.1002/cncr.25670

Table 4.

Multivariate Analysis for EFS

Parameter Mutltivariate
HR 95% CI p
A. CBF AML
FLT3 (continuous variable) 1.28 0.04–37.78 0.88
PS 1.77 1.07, 2.91 0.03
B. NK-AML (FLT3-ITD and wt-FLT3)
Age 1.02 1.01–1.03 0.005
Race (White vs Non-White) 0.56 0.39–0.81 0.002
Creatinine 1.39 1.09–1.77 0.007
FLT3-ITD (continuous variable) 3.10 1.09–8.78 0.03
Treatment (Ara-C vs. No-Ara-C) 1.65 1.05–2.59 0.03
Interaction Term
 • FLT3-ITD*Treatment 0.66 0.30–1.47 0.31
C. NK-AML (FLT3-TKD and wt-FLT3)
Age 1.03 1.01–1.04 0.0001
Race (White vs. Non-White) 0.47 0.30–0.73 0.001
Creatinine 1.47 1.03–2.09 0.003
Prior Chemotherapy/XRT 1.98 1.22–3.22 0.005
FLT3-TKD (continous variable) 0.57 0.11–2.76 0.48
Treatment (Ara-C vs. No Ara-C) 0.74 0.45–1.23 0.25
Interaction Term
 • FLT3-TKD*Treatment 0.88 0.32–2.46 0.81
D. Poor Risk AML
Age 1.02 1.01–1.04 0.01
FLT3 (continuous variable) 4.24 0.15–117.87 0.39
Treatment (Ara-C vs. No Ara-C) 1.26 0.77–2.04 0.35
Interaction Term
 • FLT3 Mut*Treatment 0.52 0.07–3.79 0.52